Clinical Trial Update: Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating guselkumab for Crohn's disease, focusing on transmural healing and potential disease-modifying effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Crohn's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING